GDC-0927( GDC0927 | SRN-927 | RG-6047 )

Catalog No. M12490 CAS No. 1642297-01-5

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Get Quotation Bulk Inquiry Add to Cart

Product Name

GDC-0927
Note

Research use only, not for human use.
Brief Description

GDC-0927 (SRN-927, RG-6047) is a potent, orally bioavailable, selective estrogen receptor degrader (SERD) for treatment of metastatic hormone receptor-positive/HER2-negative breast cancer.
Description

GDC-0927 (SRN-927, RG-6047) is a potent, orally bioavailable, selective estrogen receptor degrader (SERD) for treatment of metastatic hormone receptor-positive/HER2-negative breast cancer.Breast Cancer Phase 1 Clinical.
In Vitro

——
In Vivo

GDC-0927 is a novel, potent, non-steroidal, orally bioavailable, selective ER antagonist/ER degrader (SERD) that induces tumor regression in estrogen receptor (ER)+breast cancer (BC) patient-derived xenograft models.
Synonyms

GDC0927 | SRN-927 | RG-6047
Pathway

Endocrinology/Hormones
Target

Estrogen Receptor/ERR
Recptor

Estrogen Receptor/ERR
Research Area

Cancer
Indication

Breast Cancer

CAS Number

1642297-01-5
Formula Weight

461.533
Molecular Formula

C28H28FNO4
Purity

>98% (HPLC)
Solubility

DMSO : ≥ 100 mg/mL 216.68 mM
SMILES

CC1=C(C(OC2=C1C=C(C=C2)O)C3=CC=C(C=C3)OCCN4CC(C4)CF)C5=CC(=CC=C5)O
Chemical Name

(S)-2-(4-(2-(3-(fluoromethyl)azetidin-1-yl)ethoxy)phenyl)-3-(3-hydroxyphenyl)-4-methyl-2H-chromen-6-ol